CytoDyn (OTCMKTS:CYDY – Get Free Report) is projected to post its Q4 2026 results after the market closes on Monday, July 27th. Analysts expect CytoDyn to post earnings of ($0.05) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.
CytoDyn Trading Down 7.5%
Shares of CYDY opened at $0.20 on Friday. CytoDyn has a twelve month low of $0.19 and a twelve month high of $0.40. The firm has a market capitalization of $272.69 million, a P/E ratio of -6.60 and a beta of 1.16. The firm’s 50-day moving average is $0.27 and its two-hundred day moving average is $0.27.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Recommended Stories
- Five stocks we like better than CytoDyn
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
